• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database
【24h】

Patients with Asthma Prescribed Once-Daily Fluticasone Furoate/Vilanterol or Twice-Daily Fluticasone Propionate/Salmeterol as Maintenance Treatment: Analysis from a Claims Database

机译：哮喘患者每天一次服用氟替卡松糠酸酯/紫草醇或两次每天服用丙酸氟替卡松/沙美特罗作为维持治疗：索赔数据库中的分析

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionThere is a paucity of data describing prescribing patterns and adherence to therapy of inhaled corticosteroids (ICS) in combination with long-acting β2-agonists (LABA) in the Japanese population in clinical practice. MethodsThis was a non-interventional, retrospective, cohort study of patients who were prescribed medication for asthma, using data from the Japan Medical Data Center Claims Database. Data from patients aged?≥?15?years with a prescription of asthma drugs between December 2014 and October 2015 (Day 0, the index date when asthma medication was initiated) were analysed in 12-month pre-index and post-index periods. Part 1 focused on baseline characteristics and epidemiological outcomes in the pre- and post-index period in the overall asthma population, whereas comparing medication adherence [number of prescribed days per year and proportion of days covered (PDC)] between ICS/LABA-na?ve patients treated with once-daily fluticasone furoate/vilanterol (FF/VI) and twice-daily fluticasone propionate/salmeterol (FP/SAL) was the primary endpoint in Part 2. ResultsOf the available patient data ( N =?2,953,652), 28,699 patients were identified as having asthma. ICS/LABA was the main asthma treatment prescribed; 11,167 (38.9%) patients were continuous ICS/LABA users. In ICS/LABA-na?ve asthma patients, treatment with once-daily FF/VI was associated with higher medication adherence compared with twice-daily FP/SAL; mean [standard deviation (SD)] number of prescribed days per year was 97.8 (115.9) for FF/VI versus 80.5 (92.7) for FP/SAL ( p =?0.04), mean (SD) PDC was 26.7% (31.5) for FF/VI versus 21.9% (24.8) for FP/SAL ( p =?0.04). FF/VI was also associated with a lower rate of treatment discontinuation and no difference in use of short-acting beta2-agonists or oral corticosteroids compared with FP/SAL. ConclusionsICS/LABA was the major prescribed asthma treatment in Japan. Medication adherence was greater with FF/VI, which may indicate that patients are more likely to adhere to once-daily FF/VI versus twice-daily FP/SAL. FundingThis study was funded by GSK (study sponsor). Study RegistrationGSK Study No. 207264, GSK Study Register site: https://www.gsk-clinicalstudyregister.com/search/?search_terms=207264 .
机译：简介在临床实践中，缺乏数据描述日本人群中吸入皮质类固醇（ICS）结合长效β2-激动剂（LABA）的处方模式和治疗依从性。方法这是一项非干预性回顾性队列研究，使用日本医学数据中心理赔数据库中的数据对开了哮喘药物的患者进行了研究。在2014年12月至2015年10月（第0天，即开始哮喘药物治疗的索引日期）之间的12个月索引前和索引后期间，对≥15岁的哮喘药物处方患者的数据进行了分析。第1部分着重于整个哮喘人群在指数化前后的基线特征和流行病学结果，而在ICS / LABA-na之间比较药物依从性[每年的规定天数和所覆盖天数（PDC）的比例]在第2部分中，以每日一次糠酸氟替卡松/维兰特罗（FF / VI）和每日两次丙酸氟替卡松/沙美特罗（FP / SAL）治疗的五例患者为主要终点。结果在可用患者数据中（N =？2,953,652）， 28,699名患者被确定患有哮喘。 ICS / LABA是处方的主要哮喘治疗方法; 11,167（38.9％）位患者是ICS / LABA连续用户。在ICS / LABA初治哮喘患者中，与每日两次FP / SAL相比，每日一次FF / VI治疗与较高的药物依从性相关。 FF / VI的每年平均[标准差（SD）]规定天数为97.8（115.9），而FP / SAL为每年80.5（92.7）（p =？0.04），PDC的平均值（SD）为26.7％（31.5） FF / VI比FP / SAL为21.9％（24.8）（p =？0.04）。与FP / SAL相比，FF / VI还与较低的治疗中断率相关，并且短效β2受体激动剂或口服皮质类固醇的使用无差异。结论ICS / LABA是日本主要的处方哮喘治疗方法。 FF / VI的药物依从性更高，这表明与每日两次FP / SAL相比，患者更可能坚持每日一次FF / VI。资助这项研究由GSK（研究赞助商）资助。研究注册GSK研究编号207264，GSK研究注册网站：https://www.gsk-clinicalstudyregister.com/search/?search_terms=207264。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号